Trials / Completed
CompletedNCT00892203
Efficacy and Safety of BGG492 in the Treatment of Migraine
A Multi-centre, Randomized, Double-blind, Parallel Group, Active and Placebo Controlled, Proof of Concept Study in Patients With Acute Migraine to Assess the Efficacy, Safety and Tolerability of Single Oral Doses of BGG492
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 75 (actual)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
This study will assess the efficacy and safety of BGG492 used to treat migraine pain.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BGG492 | |
| DRUG | Sumatriptan | |
| DRUG | Placebo |
Timeline
- Start date
- 2009-04-01
- Primary completion
- 2010-08-01
- Completion
- 2010-08-01
- First posted
- 2009-05-04
- Last updated
- 2020-12-17
Locations
13 sites across 3 countries: United States, Germany, Spain
Source: ClinicalTrials.gov record NCT00892203. Inclusion in this directory is not an endorsement.